TriSalus Life Sciences bolsters board with two new members

DENVER - TriSalus Life Sciences Inc. (Nasdaq: TLSI), a $163 million market cap company focusing on improving outcomes for patients with solid tumors, has announced the addition of healthcare veterans William J. Valle and Dr. Gary B. Gordon to its Board of Directors, effective January 29, 2025. Trading at $5.33, the stock has shown resilience with a 2% gain year-to-date, according to InvestingPro data. Their appointments aim to leverage their extensive experience in medical devices and oncology drug development to advance TriSalus’s mission.

William Valle, with a notable background in medical device commercialization and reimbursement, served as CEO of North America for Fresenius Medical (TASE:PMCN) Care (NYSE:FMS) and held various executive roles within the company. Dr. Gary Gordon, recognized for his contributions to oncology drug development, has been instrumental in establishing AbbVie (NYSE:ABBV)’s oncology franchise and has been involved in the approval of significant oncology treatments. These appointments come as TriSalus demonstrates strong operational efficiency with an impressive 87.1% gross profit margin, as reported by InvestingPro.

TriSalus’s proprietary Pressure-Enabled Drug Delivery (PEDD) and Pancreatic Retrograde Venous Infusion (PRVI) systems are designed to enhance therapeutic delivery to solid tumors, including pancreatic cancer. The company’s investigational immunotherapy, nelitolimod, is currently under clinical trials to assess its efficacy in creating favorable immune responses within the liver and pancreas.

The appointments of Valle and Gordon are expected to provide strategic guidance to TriSalus as it continues to develop and commercialize its technologies. The company’s PEDD method and PRVI system hold FDA clearance, and nelitolimod is being studied for its potential to overcome immune dysfunction and drug delivery barriers.

The company has expressed optimism about the contributions the new board members will bring, given their complementary expertise in the medical device and oncology sectors. While analysts have set price targets ranging from $10 to $16, significantly above current levels, TriSalus cautions that forward-looking statements regarding the potential benefits of its technology and nelitolimod, as well as the anticipated contributions of the new board members, involve risks and uncertainties. For deeper insights into TriSalus’s financial health and additional ProTips, visit InvestingPro.

This news article is based on a press release statement from TriSalus Life Sciences.

In other recent news, TriSalus Life Sciences reported significant revenue growth of 59% for 2024, with fourth-quarter earnings reaching approximately $8.3 million. The company also projects a revenue growth in excess of 50% for 2025. TriSalus expanded its Board of Directors and appointed two new members, William Valle and Gary Gordon. Changes in the executive leadership have been announced with James Young taking the position of Chief Financial Officer, Dr. Richard Marshak as Chief Commercial Officer, and Jodi Devlin as Chief of Clinical Strategy and Operations.

Analyst firms, including Canaccord Genuity and Roth/MKM, have maintained a Buy rating on TriSalus, with price targets ranging from $10 to $16. Canaccord Genuity has adjusted its price target to $11.00, while Roth/MKM initiated coverage with a price target of $11.00.

In product development, TriSalus has launched the TriNav Large system, expected to address 30% more cases than its predecessor. Additionally, the company has integrated the TriNav catheter with a proprietary TL-9 antagonist, which is currently undergoing phase 1 evaluation. These are recent developments in the company’s ongoing growth and strategic initiatives in the medical technology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.